Pliant Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
23.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
| Q4 2026 / Full Year 2025 Earnings Release | 10 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly172.4MTarget: Sufficient to fund operations into the second half of 2028
Quarterly Net Loss Quarterly-20MTarget: Narrowing loss through disciplined spending and pipeline focus
PLN-101095 Phase 1b FORTIFY Trial Enrollment QuarterlyTarget: Complete enrollment across three cohorts (NSCLC, high TMB, ccRCC)
Watch Items
- PLN-101095 Phase 1b FORTIFY Trial Interim DataTrigger: Release of interim safety and efficacy data expected in 2027Action: Evaluate objective response rates (ORR) and safety profile in combination with pembrolizumab to determine registrational path.
- Bexotegrast (PLN-74809) Development Strategy in PSCTrigger: Long-term safety and efficacy data from the INTEGRIS-PSC Phase 2a trialAction: Assess potential initiation of late-stage clinical trials or strategic partnerships for primary sclerosing cholangitis (PSC).
- Cash Runway and Operational Burn RateTrigger: Cash balance falling below $100 millionAction: Re-evaluate clinical program prioritization or seek non-dilutive funding/licensing partnerships to extend runway beyond 2028.
Research as of 19 Jun 2026